T
Taavi Lehto
Researcher at Karolinska Institutet
Publications - 38
Citations - 2156
Taavi Lehto is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Cell-penetrating peptide & Gene delivery. The author has an hindex of 20, co-authored 34 publications receiving 1825 citations. Previous affiliations of Taavi Lehto include Stockholm University & University of Tartu.
Papers
More filters
Journal ArticleDOI
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo.
Samir El Andaloussi,Taavi Lehto,Imre Mäger,Katri Rosenthal-Aizman,Iulian I. Oprea,Oscar E. Simonson,Helena Sork,Kariem Ezzat,Dana Copolovici,Kaido Kurrikoff,Joana R Viola,Eman M. Zaghloul,Rannar Sillard,Henrik J. Johansson,Fatouma Said Hassane,Peter Guterstam,Julia Suhorutsenko,Pedro Moreno,Nikita Oskolkov,Jonas Hälldin,Ulf Tedebark,Andres Metspalu,Bernard Lebleu,Janne Lehtiö,C. I. Edvard Smith,Ülo Langel +25 more
TL;DR: A novel CPP, PepFect 6 (PF6), comprising the previously reported stearyl-TP10 peptide, having pH titratable trifluoromethylquinoline moieties covalently incorporated to facilitate endosomal release is presented, implying that the peptides, in addition to having utility for RNAi screens in vitro, displays therapeutic potential.
Journal ArticleDOI
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation
Kariem Ezzat,Samir El Andaloussi,Eman M. Zaghloul,Taavi Lehto,Staffan Lindberg,Pedro Moreno,Joana R Viola,Tarek Magdy,Rania Abdo,Peter Guterstam,Rannar Sillard,Suzan M. Hammond,Matthew J.A. Wood,Andrey A. Arzumanov,Michael J. Gait,C. I. Edvard Smith,Mattias Hällbrink,Ülo Langel +17 more
TL;DR: A new cell-penetrating peptide, PepFect14 (PF14), is presented, which efficiently delivers SCOs to different cell models including HeLa pLuc705 and mdx mouse myotubes; a cell culture model of Duchenne's muscular dystrophy; and the feasibility of incorporating this delivery system into solid formulations that could be suitable for several therapeutic applications is demonstrated.
Journal ArticleDOI
Peptides for nucleic acid delivery.
TL;DR: In conclusion, CPP-based drug delivery systems have the capacity to overcome the hurdle of delivery and thus have the potential to facilitate the clinical translation of nucleic acid-based therapeutics.
Journal ArticleDOI
Cell-penetrating peptides for the delivery of nucleic acids
TL;DR: This review will discuss recent advances of CPP-mediated delivery of nucleic acid-based cargo, concentrating on the delivery of plasmid DNA, splice-correcting ONs, and small-interfering RNAs.
Journal ArticleDOI
Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy.
Taavi Lehto,Rachida Abes,Nikita Oskolkov,Julia Suhorutsenko,Dana-Maria Copolovici,Imre Mäger,Imre Mäger,Joana R Viola,Oscar E. Simonson,Kariem Ezzat,Peter Guterstam,Elo Eriste,C. I. Edvard Smith,Bernard Lebleu,Samir El Andaloussi,Samir El Andaloussi,Ülo Langel,Ülo Langel +17 more
TL;DR: It is shown that stearyl-(RxR)(4) mediates efficient plasmid transfections in several cell lines and the expression levels are significantly higher than when using unmodified (RXR)( 4) or starylated Arg9, although the transfection efficiency is lower than with Lipofectamine 2000.